# A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Study · id `cardio:ct-nct01200394` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01200394](<https://clinicaltrials.gov/study/NCT01200394>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01200394

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

## Technical summary

Registry record NCT01200394. Randomized; double masking; primary purpose treatment. Start 2010-12 (actual); primary completion 2013-07 (actual). Results posted on 2019-03-12.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 256 participants (enrolled count; ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Started: 2010-12 (actual) (ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Primary completion: 2013-07 (actual) (ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Completion: 2013-08 (actual) (ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Results first posted: 2019-03-12 (ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Denmark; Hong Kong SAR China; India; Malaysia; Mexico; Poland; Serbia; Slovakia; South Africa; South Korea; Sweden; United Kingdom (ClinicalTrials.gov record NCT01200394, source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01200394-2019-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
- Condition: Diabetic Nephropathies
- Intervention (Drug): PF-00489791
- Intervention (Drug): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 8c6450012a7e4cce207b24310b834a4cbb518b80c6412293436835ba681c3ab3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
